Tesaro is exploring a sale, according to people familiar with the matter, two months after the cancer-treatment developer won a key drug approval.

GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.

Shares of Tesaro Inc. shot up over 58% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by GlaxoSmithKline PLC for $5.1 billion in cash. Glaxo's stock fell 3.3% ...

Tesaro won’t reveal price of its ovarian cancer drug. But it’ll likely be near $14,000 a month Published: March 29, 2017 at 8:29 a.m. ET By Emma Court ...

Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of ...

The FDA has given Tesaro a green light to start marketing rolapitant to help prevent some of the common side effects of chemotherapy. And now Tesaro will wage a David-vs.-Goliath battle for market ...

Tesaro, Inc. (NASDAQ: TSRO) is watching its shares make a significant gain on Wednesday after the company released positive late-stage trial results. The company announced that its Phase 3 NOVA ...

Investors in Tesaro (TSRO) need to pay close attention to the stock based on moves in the options market lately.

Tesaro's experimental ovarian cancer drug niraparib proved to significantly lengthen progression-free survival time in patients during a recent Stage 3 trial.

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Tesaro shares are skyrocketing today, but even it may find it difficult to keep pace with this top stock in 2014 There's a huge difference between a good stock and a stock that can make you rich.